B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

201.53 +4.34 (+2.20%)
Streaming Delayed Price Updated: 3:20 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
60 61 Next >
News headline image
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment ↗
The company is hoping to launch an under-the-skin version of its infusion, Leqembi. 
Via Investor's Business Daily
News headline image
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
From Biogen Inc.
Via GlobeNewswire
News headline image
The Analyst Landscape: 27 Takes On Biogen ↗
 
Via Benzinga
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
These Analysts Revise Their Forecasts On Biogen After Q1 Results ↗
 
Via Benzinga
News headline image
Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank ↗
Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a favorite." 
Via Benzinga
News headline image
3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024 ↗
Let’s explore three stocks that are well-positioned to rival Nvidia’s growth rates in the second half of 2024. 
Via InvestorPlace
Topics Stocks
News headline image
The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
Via InvestorPlace
News headline image
Why Is Nuvo Group (NUVO) Stock Up 200% Today? ↗
Although prenatal care specialist Nuvo Group saw its shares soar on Monday, NUVO stock faces skepticism over its SPAC merger. 
Via InvestorPlace
News headline image
Biogen Reports Progress on Corporate Responsibility Priorities
From Biogen Inc.
Via GlobeNewswire
News headline image
Where Biogen Stands With Analysts ↗
 
Via Benzinga
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
7 Retirement Stocks to Buy at a 52-Week Low in April ↗
One of the best ways to keep your portfolio safe while generating income is with dividend-paying retirement stocks at 52-week lows. 
Via InvestorPlace
Topics Retirement
News headline image
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review ↗
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
News headline image
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Why Biogen Stock Leaped Nearly 5% Higher Today ↗
The company came out swinging with its first set of quarterly earnings for this year. 
Via The Motley Fool
News headline image
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why ↗
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA... 
Via Benzinga
News headline image
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday? ↗
Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 30-year Treasury bond has surged to 4.79%. It’s on track to close at the... 
Via Benzinga
Topics Bonds
News headline image
Biogen (BIIB) Q1 2024 Earnings Call Transcript ↗
BIIB earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings ↗
Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging. 
Via Benzinga
News headline image
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024 ↗
BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? ↗
Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares? 
Via Investor's Business Daily
Topics Earnings
News headline image
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally ↗
Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semiconductor m 
Via Benzinga
News headline image
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? ↗
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week... 
Via Talk Markets
News headline image
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
News headline image
Tuesday Talk: Big-Tech Under Attack ↗
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. 
Via Talk Markets
News headline image
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.